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Abstract
Pathology is fundamental in grading, staging, and treatment planning of malignancies. One relatively novel bio-
marker that may become more important in therapy and diagnostics is the chemokine receptor 4 (CXCR4). Ac-
TZ14011 peptide derivatives, functionalized with a radiolabel, can be used for molecular imaging of tumors. Direct
fluorescent labeling of the small peptide Ac-TZ14011 with the fluorescent dye fluorescein isothiocyanate (FITC),
however, provides an alternative for the detection of CXCR4 expression levels in cells and tumor tissue. In this
study, Ac-TZ14011–FITC was validated for CXCR4 staining in human breast cancer cell lines MDAMB231 and
MDAMB231CXCR4+ during flow cytometric analysis. Its efficacy was compared to commercially available anti-
bodies. Competition experiments validated the staining specificity. Confocal imaging revealed that CXCR4 staining
was predominantly found on the cell membrane and/or in vesicles formed after endocytosis. Next to being able to
differentiate “high” and “low” CXCR4-expressing tumor cells, the fluorescent peptide demonstrates potential in
fluorescent immunohistochemistry of tumor tissue. Ac-TZ14011–FITC was able to differentiate MDAMB231 from
MDAMB231CXCR4+ tumor cells and tissue, proving its applicability in the detection of differences in CXCR4 ex-
pression levels.
Translational Oncology (2011) 4, 234–240
Introduction
The chemokine receptor 4 (CXCR4) was first detected as coreceptor
for CD4+ T-cell infection in human immunodeficiency virus type 1
[1,2]. More recently, a role for CXCR4 has been described in the
attraction of inflammatory cells [3] and the pathogenesis of rheu-
matoid arthritis [4–6]. Besides its expression in normal tissues, a
5.5-fold up-regulation of CXCR4 expression was found in breast
cancer tissue [7], and increased CXCR4 expression levels have been
reported for at least 22 other types of cancer [8,9].
The cell membrane–based interaction between CXCR4 and its
natural ligand, SDF-1 (stromal cell–derived factor 1; CXCL12), is
considered to be a driving factor [3] in its role as cellular chemo-
attractant [10]. CXCR4-based chemoattraction acts directly on tumor
cell migration and invasion toward an SDF-1 gradient [11]. High
expression levels of SDF-1 have been found at the most common
sites of breast cancer metastasis: axillary lymph nodes, lungs, liver,
and bone marrow [11–13]. Furthermore, overexpression of CXCR4
and/or SDF-1 has been correlated to worsened prognosis and disease-
free survival [14–17]. Because CXCR4 plays an important role in the
malignancy/metastasis of cancer, it is considered a candidate bio-
marker for evaluating cancer progression and perhaps the selection/
monitoring of treatment strategies.
Recently, a lot of effort has been conducted in the development
of CXCR4-specific antagonistic peptides. Small peptides, such as
T140 and its derivative Ac-TZ14011, were selected based on their
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antagonistic properties toward the CXCR4 receptor and their poten-
tial for treatment. These and several other peptide derivatives have
been used to reduce cell proliferation and migration in vitro and to
cause inhibition of primary tumor growth and tumor metastasis
in vivo [18–23]. A useful property of the Ac-TZ14011 peptide is that
it has one free lysine group situated at a significant distance from the
pharmacophore allowing functionalization with a single diagnostic an-
tenna. For example, an 111In-labeled DTPA-Ac-TZ14011–derivative
has shown potential during the noninvasive imaging of the CXCR4
expression in vivo [23,24].
Because CXCR4 is part of a family of membrane-bound G protein–
coupled receptors, staining of the cell surface membrane could be con-
sidered most representative. However, immunohistochemistry (IHC)
on breast cancer tissue using antibodies directed against CXCR4 has
shown staining of the cell surface membrane, the cytoplasm, and the
nucleus of the cell [12–16,25]. Such differences between IHC locali-
zation and its natural role may present actual changes in the localiza-
tion of CXCR4 or may be caused by the staining techniques used.
Another downside of using antibodies for IHC is that the agent used
for detection will differ from the peptides used in vivo.
Ideally, ex vivo validation is performed using a detection agent that
accurately resembles the compound used for imaging. Nishizawa et al.
[26] have demonstrated the value of the fluorescein-labeled T140
derivative TY14003 in the detection of high-grade bladder cancer.
Hence, we reasoned that a fluorescent derivative of Ac-TZ14011
[27] can also potentially be used for fluorescent IHC (FIHC) of breast
tumor tissue.
We here report on the use of the Ac-TZ14011–fluorescein isothio-
cyanate (FITC) peptide for FIHC of CXCR4-overexpressing cells/
tumors. In this study, we compared its efficacy in detecting CXCR4 ex-
pression to that of the commercially available anti-CXCR4 antibodies.
Materials and Methods
Cell Culture
Humanbreast cancer cell linesMDAMB231 andMDAMB231CXCR4+
were kindly provided by Olaf van Tellingen and Ed Roos (NKI-AvL,
Amsterdam, the Netherlands), respectively. MDAMB231CXCR4+ cells
express higher levels of CXCR4 expression and have been selected using
flow cytometry. MDAMB231 cells were used as control based on their
basal CXCR4 expression. Both cell lines were maintained in Gibco’s
minimum essential medium enriched with 10% fetal bovine serum,
penicillin, streptomycin L-glutamine, nonessential amino acids, so-
dium pyruvate, and minimum essential medium vitamins solution
(Life Technologies Inc, Breda, the Netherlands). Cells were kept
under standard culture conditions.
Flow Cytometry
Cell staining. Freshly culturedMDAMB231 orMDAMB231CXCR4+
cells were trypsinized, washed with 0.1% bovine serum albumin in
phosphate-buffered saline (0.1% BSA/PBS) and then incubated for
1 hour with monoclonal phycoerythrin (PE) labeled anti-CXCR4
antibody (12G5-PE (1:5) or 2B11-PE (1:100); BD Biosciences, Breda,
the Netherlands) or with Ac-TZ14011–FITC (1:200; for the prepa-
ration of Ac-TZ14011–FITC, see Supporting Information). Cells were
labeled on ice or at room temperature (RT). After incubation, cells
were washed with 0.1% BSA/PBS, and 5 minutes before analysis, pro-
pidium iodide (PI; 1:10000; BD Biosciences) was added to distinguish
live and dead cells.
For fixed cell conditions, cells were trypsinized, washed with 0.1%
BSA/PBS, and fixed with formalin overnight, again washed with
0.1% BSA/PBS, and then for 1 hour incubated with 12G5-PE,
2B11-PE, or Ac-TZ14011–FITC on ice, followed by washing with
0.1% BSA/PBS.
Peptides and antibodies were diluted in 0.1% BSA/PBS in all flow
cytometry experiments. Non–antibody/peptide–incubated cells served
as controls.
SDF-1 and Ac-TZ14011 competition experiment. One hour be-
fore the start of the experiment, MDAMB231 or MDAMB231CXCR4+
cells were given fresh culture medium. After trypsinization, 6.0 ×
106 cells/ml were incubated for 1 hour on ice with 12G5-PE and
SDF-1 (8.87 nM), Ac-TZ14011–FITC and SDF-1 (0.67 μM) or
Ac-TZ12011–FITC and unlabeled Ac-TZ14011 (0.67 and 6.70 μM,
respectively). Cells were washed with 0.1% BSA/PBS, PI was added,
and cells were analyzed.
CXCR4 chemokine receptor expression-level determination using
FACS. After staining, cells were analyzed using a Beckton Dickinson
FACSCalibur (BD Biosciences) equipped with Cell Quest Pro software
(BD Biosciences). FITC fluorescence was detected in the FL1 channel
(excitation, 488 nm; emission filter, 530/30 nm). PE fluorescence was
detected in the FL2 channel (excitation, 488 nm; emission filter, 585/
42 nm). PI was detected in the FL3 channel (excitation, 488 nm; emis-
sion filter, >670 nm).
Mean fluorescent signal intensity ratios (MFIRs) were calculated as:
(mean fluorescent signal intensity signal antibody or peptide incubated
condition) / (mean fluorescent signal intensity control condition).
To determine statistical significance between the different cell lines
(Table 1) or the different incubation conditions (Tables 2 and W1), a
standard t test was performed. All experiments were performed at least
in triplicate.
Generation of Mouse Tumor Models
Before injection in vivo, cells were washed three times with Hanks
buffered salt solution (Life Technologies Inc) and resuspended
Table 1. CXCR4 Expression on MDAMB231 and MDAMB231CXCR4+ Cells Incubated at Dif-
ferent Conditions (n = 3-6).







Live cells; on ice 1.116 ± 0.054 4.920 ± 1.463 4.4*
Live cells; RT 1.160 ± 0.108 8.747 ± 1.245 7.5†
Fixed cells; on ice 7.380 ± 3.573 11.046 ± 2.143 1.5
2B11-PE
Live cells; on ice 1.179 ± 0.072 1.487 ± 0.051 1.3†
Live cells; RT 1.206 ± 0.047 1.435 ± 0.042 1.2†
Fixed cells; on ice 18.814 ± 6.636 13.378 ± 3.267 0.7
Ac-TZ14011–FITC
Live cells; on ice 2.337 ± 0.341 5.505 ± 0.900 2.4†
Live cells; RT 2.970 ± 0.289 4.941 ± 0.487 1.7*
Fixed cells; on ice 25.788 ± 1.575 62.357 ± 7.920 2.4†
For significance: MDAMB231 MFIRs were compared to MDAMB231CXCR4+ MFIRs.
*P ≤ .05.
†P ≤ .005.
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in Hanks buffered salt solution to a final concentration of 50.0 ×
107 cells/ml and kept on ice.
Female BALB/c nude mice, 6 to 8 weeks old, were anesthetized with
a mixture of hypnorm (Vetapharma, Leeds, United Kingdom), dor-
micum (Roche Diagnostics GmbH, Mannheim, Germany), and water
suitable for injection (1:1:2; 5 μl/g intraperitoneally). MDAMB231 or
MDAMB231CXCR4+ cells (1.0 × 106) were orthotopically injected
into the left inguinal mammary fat pad. Because CXCR4 expression
in the lymph nodes is intrinsically high, the left inguinal lymph node
was cleared before injection of the tumor cells, hereby creating a low-
background niche for the tumor cells to grow in. At 6 to 8 weeks after
transplantation, mice were killed, and primary tumors (∼4 cm3) were
taken out (n = 20). Hereafter, fresh tumor tissue could be analyzed, or
the tumor tissue was formalin-fixed and paraffin-embedded and used
for IHC and FIHC.
All animal experiments were performed in accordance with Dutch
animal welfare regulations and approved by the local ethics committee.
Immunohistochemistry
Formalin-fixedparaffin-embeddedMDAMB231orMDAMB231CXCR4+
tumor tissue sections, 4 μm in size, were deparaffinized. Sections were
heated for 30 minutes at 95°C in citrate buffer (pH 6) to retrieve anti-
genic activity, followed by 30 minutes cooling at RT. For antibody
12G5, slides were incubated for 30 minutes with protein kinase or
20 minutes with trypsin at 37°C or heated for 30 minutes at 95°C in
Tris/EDTA (pH 9) followed by 30 minutes cooling at RT. Slides were
rinsed with PBS and incubated overnight at 4°C with a monoclonal
anti–CXCR4-antibody (clone 2B11 [1:100; n = 5-10] or clone 12G5
[1:100; n = 3]; BDBiosciences). After washing, slides were incubated for
1 hour at RTwith the secondary antibody, goat-anti-rat (sc-2041; 1:100;
Santa Cruz Technology, Heidelberg, Germany) or with goat-anti-mouse
(E0433; 1:500; DAKO, Glostrup, Denmark) for clones 2B11 and
12G5, respectively. Negative controls were only incubated with the sec-
ondary antibody. Slides were then washed and incubated for 30minutes
with horseradish peroxidase–labeled streptavidin-biotin complex
(1:200; DAKO). Slides were developed with 3,3′-diamobenzidine
tetrahydrochloride (Sigma-Aldrich, Zwijndrecht, the Netherlands)
and slightly counterstained with hematoxylin (Sigma-Aldrich). Images
were taken with a color CCD microscope system (Axiovert S100 with
AxioCam HRc; Carl Zeiss BV, Sliedrecht, the Netherlands) and ana-
lyzed using AxioVision (Carl Zeiss).
Confocal Imaging
Fluorescent immunohistochemistry of formalin-fixed paraffin-
embedded tumor tissue. After deparaffinization, antigen retrieval
incubation, and three PBS washes (as described in the IHC section),
slides were incubated for 1 hour at RT with Ac-TZ14011–FITC
(1:200; n = 3). Thereafter, slides were washed with PBS, counter-
stained with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI;
1:1000; Roche Diagnostics GmbH) and washed thoroughly. Nega-
tive controls were only incubated with DAPI. Slides were mounted
with Vectashields mounting medium for fluorescence to preserve the
fluorescent signal (Vector Laboratories Inc, Burlingame, CA).
In vitro immunofluorescence. Before the start of the experiment,
1.0 × 105 MDAMB231 and MDAMB231CXCR4+ cells were seeded
at coverslips (Ø 24 mm; Karl Heicht GmbH&Co, Sondheim, Ger-
many). After 24 to 48 hours (80% confluency), cells were washed with
PBS and incubated for 1 hour on ice or at RT with Ac-TZ14011–
FITC (1:200) and washed again with ice-cold PBS. Cells were stored
in PBS on ice until analysis. For the internalization experiment, images
were taken 15, 30, and 60minutes after the t = 0 image was taken. Cells
were warmed with RT PBS.
For fixed cell conditions, cells were placed in formalin overnight,
washed with PBS, and then incubated for 1 hour on ice with Ac-
TZ14011–FITC. After washing with ice-cold PBS confocal images
were taken. Non–peptide-incubated slides served as negative control.
Ex vivo fluorescent tumor tissue imaging. MDAMB231 or
MDAMB231CXCR4+ tumor-bearing mice were killed, and excised tu-
mor tissue was formalin-fixed for 24 hours (n = 3). After slicing, tis-
sue was incubated for 1 hour with Ac-TZ14011–FITC (1:200)
followed by PBS washes and incubation with DAPI (1:1000) for
10 minutes and again thoroughly washed with ice-cold PBS.
Results
In the present study, we investigated the use of a FITC-labeled antag-
onistic CXCR4 peptide, Ac-TZ14011–FITC, in direct fluorescence-
based visualization of the CXCR4 expression levels in MDAMB231
and MDAMB231CXCR4+ cells and tumors derived thereof.
Determination of the Specificity of Ac-TZ14011–FITC
for CXCR4
To make sure the synthesized antagonistic CXCR4 peptide (Ac-
TZ14011–FITC) specifically stains CXCR4, its specificity was validated
using flow cytometric analysis. MFIRs of MDAMB231 (low CXCR4
expression) andMDAMB231CXCR4+ (highCXCR4 expression) showed
a 2.4 times (P = .0003) higher signal intensity on MDAMB231CXCR4+
cells compared with MDAMB231 cells when live cells were incubated
on ice with Ac-TZ14011–FITC (Table 1). However, after incubation
at RT, only a 1.7 times (P = .04) higher signal intensity could be de-
tected onMDAMB231CXCR4+ cells (Table 1). PE-labeled anti-CXCR4
antibody clones 12G5 or 2B11 (referred to as 12G5-PE or 2B11-PE,
respectively) were used as a reference staining. As can be seen in Table 1,
after incubationwith 12G5-PE, a 4.4 times higherMFIR (P = .01) could
be detected in MDAMB231CXCR4+ cells compared with MDAMB231
cells. Incubation at RT resulted in a 7.5 times higherMFIR (P = .0012).
For 2B11-PE, the measured difference in MFIR was only 1.3 times
Table 2. Antagonistic Ac-TZ14011–FITC Competes with SDF-1 and Ac-TZ14011 for the
CXCR4 Receptor (n = 3).
Cell Type
MDAMB231 MDAMB231CXCR4+
MFIR ± SD % MFIR ± SD %
12G5-PE 1.134 ± 0.033 2.186 ± 0.048
SDF-1 + 12G5-PE 1.174 ± 0.009 +3 2.015 ± 0.080 −8
Ac-TZ14011–FITC 1.900 ± 0.049 6.905 ± 0.174
SDF-1 + Ac-TZ14011–FITC 2.010 ± 0.044 +6 4.643 ± 0.339 −33*
Ac-TZ14011 + Ac-TZ14011–FITC 2.266 ± 0.095 +19† 2.985 ± 0.291 −57*
For significance: 12G5-PE/Ac-TZ14011–FITC MFIRs were compared to MFIRs of SDF-1/
unlabeled Ac-TZ14011 + 12G5-PE/Ac-TZ14011–FITC incubated conditions.
% indicates percentage change in fluorescent signal intensity.
*P ≤ .005.
†P ≤ .05.
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(P = .003) and 1.2 times (P = .0035) higher when incubated on ice
or at RT.
When formalin-fixed cells were stained with Ac-TZ14011–FITC for
CXCR4, signal intensities and thereby the MFIRs increased for both
MDAMB231 (MFIR 25.788 ± 1.575) and MDAMB231CXCR4+
(MFIR 62.357 ± 7.920) cells. However, the ratio between the two
remained identical to that in live cells incubated on ice, namely, 2.4
(P < .0001). Significant differences could no longer be detected when
formalin-fixed MDAMB231 and MDAMB231CXCR4+ cells were in-
cubated with 12G5-PE (MFIRs 7.380 ± 3.573 and 11.046 ± 2.143,
P = .22) or 2B11-PE (MFIRs 18.814 ± 6.636 and 13.378 ± 3.267,
P = .29; Table 1).
SDF-1 Competition Experiment
To further determine the binding specificity and affinity of the Ac-
TZ14011–FITC peptide for the CXCR4 receptor, an SDF-1 com-
petition experiment was performed (Table 2). SDF-1 was added to
occupy the CXCR4 receptors, hereby preventing Ac-TZ14011–FITC to
bind to the receptor. In the presence of Ac-TZ14011–FITC and SDF-1,
the MFIR decreased with 33% compared with MDAMB231CXCR4+
cells that were incubated with Ac-TZ14011–FITC alone (from 6.905 ±
0.174 to 4.643 ± 0.339, P = .002). A slight increase (6%) in MFIR
was found when MDAMB231 cells were incubated with Ac-TZ14011–
FITC and SDF-1 (from 1.900 ± 0.049 to 2.010 ± 0.044, P = .17). Co-
incubation of 12G5-PE and SDF-1 resulted in an 8% decrease of MFIR
in MDAMB231CXCR4+ (from 2.186 ± 0.480 to 2.015 ± 0.080, P =
.13), where the MFIR of MDAMB231 cells increased with 3% (from
1.134 ± 0.033 to 1.174 ± 0.009, P = .29). For blocking experiments
with SDF-1, see Supporting Information.
Ac-TZ14011 Competition Experiment
Competition with the parental Ac-TZ14011 peptide was used to
underline the specificity of Ac-TZ14011–FITC. When cells were co-
incubated with an excessive amount of unlabeled Ac-TZ14011 and
Ac-TZ14011–FITC, theMFIR of MDAMB231CXCR4+ cells decreased
with 57% (from 6.905 ± 0.174 to 2.985 ± 0.291, P = .0041). The
MFIR of MDAMB231 cells increased with 19% (from 1.900 ± 0.049
to 2.266 ± 0.095, P = .0095).
Ac-TZ14011–FITC Distribution in Cultured Tumor Cells
Confocal images help to determine the cellular localization of Ac-
TZ14011–FITC after binding to the cells. As Figure 1A shows, on
MDAMB231 cells, (i) only a faint membranous staining could be de-
tected. In MDAMB231CXCR4+ cells, a much higher degree of mem-
branous staining could be detected (ii). Where initial staining was
predominantly membranous, images taken over time (t = 0-60 min;
Figure 1C ) revealed progressive internalization of the fluorescent signal
into the cell. Here, endocytosis resulted in internalization of Ac-
TZ14011–FITC in vesicle-like structures visible in the cytoplasm.
Incubation on ice of formalin-fixed cells with Ac-TZ14011–FITC
yielded an entirely different staining pattern. Ac-TZ14011–FITC was
found throughout the entire cell, in both MDAMB231 (Figure 1Bi)
and MDAMB231CXCR4+ (Figure 1Bii) cells. However, the staining in
MDAMB231CXCR4+ cellswasmore intense than that ofMDAMB231 cells.
Ac-TZ14011–FITC for FIHC
Standard IHC was performed to determine the CXCR4 expression in
tumor tissue. Using the 12G5 antibody, only a minor degree of staining
could be detected in theMDAMB231 tumor tissue.MDAMB231CXCR4+
tumor tissue, however, stained brownish all over but no clear cyto-
plasmatic or membranous staining could be discriminated. Because the
control tissue (only incubated with secondary antibody) showed a sim-
ilar staining pattern (data not shown), these results were deemed non-
specific. Different antigen retrieval steps were evaluated, but this did
not reveal in any specific staining of the tissue (data not shown).
Incubation ofMDAMB231CXCR4+ tissue with the 2B11 antibody re-
sulted in strongly positively stained regions. In these regions, both mem-
branous and cytoplasmatic staining could be detected (Figure 2Bii).
In comparison, little to no staining was detected on MDAMB231 tu-
mor tissue (Figure 2Bi). The negative control slides showed no non-
specific staining.
To our surprise, deparaffinized MDAMB231 tumor tissue incu-
bated with Ac-TZ14011–FITC showed strong nonspecific staining
in the nuclear membrane, nucleoli, and connective tissue (Figure 2Ci).
MDAMB231CXCR4+ tumor tissue slides, however, showed a some-
what different staining profile with predominantly cytoplasmatic and
membranous staining (Figure 2Cii).
When tumor tissue was not paraffin-embedded but only formalin-
fixed for 24 hours, Ac-TZ14011–FITC staining of MDAMB231CXCR4+
tumor tissue (Figure 2Dii) was much more intense compared with
MDAMB231 tumor tissue (Figure 2Di). This result is in line with the
difference in staining intensity observed with 2B11 (Figure 2, Bi and ii).
However, as can be seen in Figure 2, Di and ii, staining was detected
throughout the entire cell, and staining was not confined to the mem-
brane and cytoplasm. This staining pattern in fixed tissue is highly similar
to that observed in fixed cells (see above Figure 1Bi and ii). For tumor
staining patterns after intravenous administration of Ac-TZ14011–FITC,
see the Supporting Information.
Discussion
Both for therapeutic and diagnostic applications, pathology, or rather
IHC, is considered the standard in determination of the CXCR4
expression levels in tumor tissue. In this study, we investigated the po-
tential of the fluorescent peptide Ac-TZ14011–FITC in fluorescence-
based detection of CXCR4 expression levels. Other than conventional
antibody-based IHC procedures, this fluorescent derivative of Ac-
TZ14011 may, in the future, be used to visualize exactly the same fea-
tures at FIHC as can be detected in noninvasive single-photon emission
computed tomography imaging using the radioactive derivative 111In-
DTPA-Ac-TZ14011.
A discussion regarding the use of CXCR4-overexpressing cell lines
rather than CXCR4-transfected cell lines is provided in the Support-
ing Information section.
CXCR4 Affinity of Ac-TZ14011–FITC
After validating the ability of Ac-TZ14011–FITC to discriminate
between MDAMB231 and MDAM231CXCR4+ cells (Table 1), the af-
finity of Ac-TZ14011–FITC for CXCR4 was further validated with
competition (and blocking) experiments. Competition with SDF-1
gave a 33% reduction in peptide binding to the MDAM231CXCR4+
cells (Table 2). Blocking gave a 29% reduction (Table W1). It can
be concluded that SDF-1 has a higher affinity for CXCR4 than
Ac-TZ14011–FITC, which is in accordance with results found by
Nomura et al. [28]. For the antibody 12G5-PE, we were not able
to induce a significant reduction in uptake during a competition ex-
periment with SDF-1, suggesting both can simultaneously interact
with CXCR4.
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Experiments with the “low” CXCR4-expressing MDAM231 cells
show an increase in peptide binding (Tables 2 and W1), of which
only the 19% obtained after coincubation with an excess of Ac-
TZ14011 is significant. Most likely, the high extracellular concentra-
tion of Ac-TZ14011 drives nonspecific uptake, also resulting in an
increase in uptake of the structurally very similar Ac-TZ14011–FITC
derivative. This effect, however, does not seem to dominate in the
MDAM231CXCR4+ cells.
Cellular Localization of CXCR4
Using different antibodies, positive staining of the cell membrane,
the cytoplasm, and even the nucleus has been reported [10,12–
16,29,30]. However, as previously mentioned by Fischer et al. [29]
and Kryczek et al. [30], nuclear localization would not be compatible
with CXCR4 being a membrane receptor and its function in cancer
cell migration and homing. Hence, membranous staining is considered
most representative. Identical with the results published by Nomura
et al. [28] and Zhang et al. [31], we found that Ac-TZ14011–FITC
predominantly binds to CXCR4 on the cell membrane (Figure 1A)
when live cells were incubated with Ac-TZ14011–FITC. Further-
more, membrane Ac-TZ14011–FITC-CXCR4 complexes internalized
into the cell in small cytoplasmic vesicles (Figure 1C ) [28,31]. Ac-
TZ14011–FITC distribution throughout the entire cell was only ob-
served when fixed cells or tissues were incubated. These results suggest
fixation may influence the distribution of the staining agent.
Viable versus Fixed Material
Confocal images helped resolve questions about the difference in
signal intensity seen with flow cytometry between live and fixed cells
(Figure 1 and Table 1). The distribution of Ac-TZ14011–FITC in
fixed cells, wherein the whole cell was stained, was completely differ-
ent from the distribution observed in viable cells. Formalin slightly
Figure 1. Ac-TZ14011–FITC distribution in live and formalin-fixed MDAMB231 and MDAMB231CXCR4+ tumor cells. (A) Live MDAMB231
and MDAMB231CXCR4+ cells were incubated with Ac-TZ12011–FITC for 1 hour on ice. (B) Formalin-fixed cells were incubated for 1 hour
with Ac-TZ12011–FITC on ice. (C) MDAMB231CXCR4+ cells were incubated for 1 hour with Ac-TZ12011–FITC on ice, and confocal images
were taken (t = 0 minute). Over time, Ac-TZ12011–FITC-CXCR4 receptor complexes internalized via vesicles (t = 0–60 minutes). Original
magnification, ×630.
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permeabilizes the cell membranes, which might induce cellular and
nuclear uptake of Ac-TZ14011–FITC. Although the fixed cells stained
positive all over, the staining intensity of MDAMB231CXCR4+ cells was
more intense than seen in MDAMB231 cells, which is in accordance
with the results obtained with flow cytometry (Table 1). Fixation arti-
facts may also be of influence on the distribution patterns observed at
IHC, and the latter may thus not accurately represent the CXCR4
expression patterns in viable tissue.
In addition to fixation, paraffinization also had a negative influ-
ence on the peptide-based staining (Figure 2C). A clear differentiation
could, however, be made on only formalin-fixed tissue (Figure 2D).
Antibodies versus Peptides
During this study, anti-CXCR4 antibody clones 12G5 and 2B11
were used as reference. These antibodies differ in the “type” of CXCR4
that they recognize; where antibody 12G5 is directed against human
origin CXCR4, antibody 2B11 is directed toward murine CXCR4.
In flow cytometry of viable cells, the 12G5-PE antibody was able to
nicely distinguish MDAMB231 from MDAMB231CXCR4+ cells,
whereas the 2B11-PE antibody did not perform as well (Table 1).
However, when the cells were fixed, neither of the antibodies was able
to distinguish between the two cell lines. Surprisingly, in IHC, an op-
posite effect was observed; anti-murine 2B11 antibody gave specific
staining on the human-originated MDA tumors, whereas anti-human
12G5 antibody did not (FigureW1, Ai and ii). This observation under-
lines that antibodies are not always interchangeable between different
detection viz. flow cytometry and IHC, whereas Ac-TZ14011–FITC
peptide can be used in both cases.
To overcome both the need of using different antibodies for flow
cytometry and IHC staining, Ac-TZ14011–FITC can be used. This
peptide showed corresponding results in studies on cells and tumor
tissue (Table 1 and Figures 1B and 2D). Clearly, this will be most
beneficial for evaluation of the more “experimental” biomarkers such
as CXCR4 and in combination with multispectral FIHC that allows
for the simultaneous detection of multiple biomarkers at once.
The main advantage of using peptides for IHC visualization of
CXCR4 is that it makes it easier to directly correlate IHC stainings with
imaging findings obtained using the 111In-DTPA-Ac-TZ14011 analog.
Such a combination of differently labeled derivatives of the same peptide
sequence would improve the integration of in vitro and in vivo diag-
nostics. Of course, a similar approach may be achieved using a combi-
nation of, for example, 125I-12G5 and 12G5-PE [32]. However, using
an antibody takes away the advantages small molecules such as peptides
have. Moreover, it would make it more difficult to measure/predict
therapy response based on treatment with CXCR4-inhibitory peptides.
Signal intensity differences obtained in flow cytometry varied be-
tween 12G5-PE and Ac-TZ14011–FITC (Table 1). While the latter
shows significant differences under all the conditions studied, 12G5-
PE showed larger differences between the live conditions studied in
MDAMB231 and MDAMB231CXCR4+ cells. This result suggests that,
with Ac-TZ14011–FITC, there is somewhat more nonspecific cellular
uptake than with 12G5-PE.
Ex Vivo Visualization of CXCR4 Expression in Tumor Tissue
During ex vivo (F)IHC, the peptide/antibody has access to the
whole tumor tissue slide and, therefore, is able to stain all CXCR4
Figure 2. Predominant cytoplasmatic CXCR4 expression on formalin-fixed paraffin-embedded and freshly isolated, formalin-fixed, breast
cancer tissue. (A) Formalin-fixed paraffin-embedded slides were incubated with the primary anti-CXCR4 antibody clone 12G5, (B) primary
anti-CXCR4 antibody clone 2B11 (original magnification, ×400; n= 5-10), or (C) incubated with Ac-TZ12011–FITC (original magnification,
×630; n = 3). (D) Freshly isolated, formalin-fixed tumor tissue incubated with Ac-TZ12011–FITC showed a different staining pattern.
Original magnification, ×630; n = 3.
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present. Intravenously administrated Ac-TZ14011–FITC (see Sup-
porting Information) predominantly has access to the blood supplied
areas of the tumor and will only provide a specific signal after binding
of extracellular expressed CXCR4 (Figures 1C and W1B). Hence, this
only gave local staining. The intravenous incubation demonstrates
how Ac-TZ14011-FITC can visualize the staining efficacy that would
be achieved using the molecular imaging agent 111In-DTPA-Ac-
TZ14011. This application illustrates how the Ac-TZ14011 peptide
(and perhaps many others), in combination with different diagnostic
“antennae,” can, in the future, be used to directly correlate in vivo
findings with ex vivo stainings.
Conclusions
In conclusion, the present study illustrates the value of Ac-TZ14011–
FITC to identify tumor cells with slightly upregulated CXCR4 ex-
pression levels. The fluorescent peptide antagonist can be used during
both FIHC and flow cytometry. Where results with antibodies rely on
employment of different antibodies for different applications, Ac-
TZ14011–FITC is widely applicable. The peptide application in
FIHC broadens the diagnostic application of Ac-TZ14011 from a
use in vitro, in vivo, and now even ex vivo.
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Methods
Ac-TZ14011–FITC synthesis. The antagonistic CXCR4 peptide,
Ac-TZ14011, was synthesized as described previously [1]. A stock
solution of Ac-TZ14011–FITC of 1 mg/ml in 5% ethanol in water
was made. Aliquots of this stock were stored at −20°C and, when
necessary, an aliquot was diluted before the experiment and the di-
lution factor is indicated for each experiment.
Fluorescein isothiocyanate isomer I (FITC; 2.32 mg, 5.95 μmol) in
500 μl of dimethyl sulfoxide was added to the antagonistic CXCR4 pep-
tide (11.1 mg, 3.96 μmol) in 1ml of 0.1MNaHCO3 (Merck, Schiphol-
Rijk, the Netherlands) and 2 ml of CH3CN (Acros, Geel, Belgium). The
mixture was stirred overnight at RT, solvents were evaporated, and the
product was purified by preparative high-performance liquid chromatog-
raphy using a Waters HPLC system with a UV detector operating at
230 nm and aWaters Atlantis C18 10 μm (250 × 19 mm) column using
a gradient of 0.05% trifluoroacetic acid (Sigma-Aldrich) in H2O/
CH3CN 9:1 to 0.05% trifluoroacetic acid in H2O/CH3CN 1:4 in
40minutes. A yellow fluffy solid (4.3mg, 35%)was obtained after lyoph-
ilization of the pooled fractions and characterized by MALDI-TOF-MS.
The fluorescein-labeled CXCR4 peptide antagonist will be re-
verted to as Ac-TZ14011–FITC from here on. All experiments were
performed in the absence of light when fluorescent labels were used.
Cell staining: SDF-1 block experiment. One hour before the start
of the block experiment, MDAMB231 or MDAMB231CXCR4+ cells
were given fresh culture medium. After trypsinization, 2.0 × 106 cells/ml
were incubated for 1.5 hours at 37°C with 1.5 μg of SDF-1 (Peprotech
via Bio Connect, Huissen, the Netherlands) in culture medium. SDF-1
was removed by centrifugation (5 min, 1200 rpm, 4°C), and cells were
resuspended at 6.0 × 106 cells/ml before incubation on ice for 1 hour
with 12G5-PE or Ac-TZ14011–FITC. Hereafter, cells were washed
with 0.1% BSA/PBS, PI was added, and cells were analyzed.
Ex vivo detection after intravenous administration of Ac-TZ14011–
FITC. In addition, MDAMB231 or MDAMB231CXCR4+ tumor-
bearing mice were intravenously injected with 50 μg of Ac-TZ14011–
FITC (n = 3). Twenty-four hours after injection, mice were killed,
and tumors were excised and kept in PBS or formalin on ice. Then,
thin slices were cut, washed with ice-cold PBS, incubated for 10 min-
utes with DAPI, and again thoroughly washed before images of the
fresh tumor tissue were obtained. Furthermore, excised tumors were
formalin fixed on ice for 3 hours, cut into thin slices, and washed with
ice-cold PBS and incubated with DAPI before confocal images were
obtained. Controls were only incubated with DAPI before imaging.
Confocal microscope properties. Confocal images were taken on a
Leica TCS-SP2-AOBS live confocal microscope (Leica Microsystems
Heidelberg, GmbH, Heidelberg, Germany; magnification, ×400/
×630).DAPIwas excited at 405 nm, and emissionwas detected between
409 and 468 nm. FITC was excited at 488 nm, and emission was de-
tected between 510 and 585 nm. A Leica TCS-NT confocal microscope
(Leica Microsystems Heidelberg GmbH; magnification, ×630) with
Leica Confocal Software was used to analyze the MDAMB231 and
MDAMB231CXCR4+ Ac-TZ14011–FITC–incubated tumor cells.
Emission of FITC was detected between 510 and 585 nm. Pictures
were captured, and overlays were made using Leica Confocal Software
(Leica Microsystems Heidelberg GmbH).
Results
SDF-1 block experiment. On binding of SDF-1, the CXCR4 re-
ceptor internalizes and becomes cleared from the membrane [1,2].
To study this effect, MDAMB231CXCR4+ cells were preincubated
for 1.5 hours with SDF-1 at 37°C. After removal of the excess SDF-1
in solution, cells were incubated with 12G5-PE or Ac-TZ14011–FITC
for 1 hour on ice to determine the amount of CXCR4 left on the
cell membranes. As can be seen in Table W1, preincubation of
MDAMB231CXCR4+ cells with SDF-1 followed by Ac-TZ14011–
FITC incubation revealed 29% decrease in MFIR compared with
incubation with Ac-TZ14011–FITC alone (from 5.184 ± 0.144 to
3.699 ± 0.034, P = .0037). In addition, 14% less 12G5-PE was bound
by MDAMB231CXCR4+ cells that were preincubated with SDF-1 fol-
lowed by 12G5-PE incubation (MFIR decreased from 1.485 ± 0.018
to 1.274 ± 0.033, P = .0043), indicating that 14% of the CXCR4
receptors internalize after binding SDF-1.
The SDF-1 block experiment was not performed for MDAMB231
cells because these already show limited CXCR4 expression levels in
the absence of SDF-1.
FIHC of tumors after intravenous Ac-TZ14011–FITC administra-
tion in mice. Alternative to ex vivo tissue incubation with Ac-
TZ14011–FITC, this peptide can also be used for in vivo (intravenous)
tumor staining. Mice bearing MDAMB231 or MDAMB231CXCR4+
tumors were intravenously injected with Ac-TZ14011–FITC. Tumors
were excised after 24 hours wherein the tumor tissue was analyzed using
a confocal microscope (a schematic overview is given in Figure W1A).
After intravenous incubation, MDAMB231CXCR4+ tumor tissue slices
regionally stained positive for CXCR4 (Figure W1Bii). Under these
conditions, MDAMB231 tumor tissue (Figure W1Bi) hardly stained
positive for CXCR4.
Formalin fixation of the Ac-TZ14011–FITC preincubated tis-
sue still predominantly revealed cytoplasmic staining for CXCR4
on MDAMB231CXCR4+ tumor tissue slices (Figure W1Cii) where
MDAMB231 tumor tissue again stained weakly positive (Fig-
ure W1Ci). Importantly, the background signal found on formalin-
fixed tumor tissue slices was relatively low (Figure W1, B and C).
Discussion
CXCR4-overexpressing cell lines rather than CXCR4-transfected cell
lines. The CXCR4-negative and -positive cell lines used have a small
(factor = 2.4-7.5) difference in CXCR4 expression levels (Table 1).
Clearly, this minor difference makes it more difficult to differentiate be-
tween the two expression levels using FIHC.This is especially so because
the MDAMB231 cell line cannot be considered completely CXCR4-
negative but has a basal CXCR4 expression. CXCR4-transfected and/
or downregulated cell lines would make the differences much clearer.
However, we reasoned that differences in clinical breast tumor sam-
ples would also be marginal because an up-regulation factor of 5.5 has
been reported [3].
Because of this similarity in overexpression, we consider the differ-
ence between our MDAMB231 cell lines more representative for the
clinical situation, and thus, this experimental setup may better predict
the potential clinical value of the approach.
Intravenous administration of Ac-TZ14011–FITC. To over-
come the fixation artifacts seen in fixed cells and tumor tissue and
to study CXCR4 expression of the tumor tissue in its most natural
environment, Ac-TZ14011–FITC was intravenously administrated to
tumor-bearing mice (Figure W1A). Analysis of the freshly isolated tis-
sue before or after fixation revealed stronger staining of the cytoplasm
of MDAMB231CXCR4+ tumor tissue compared with MDAMB231 tu-
mor tissue (Figure W1, B and C). Because it can be expected that the
membranous staining in these tumor cells is internalized after the in-
cubation period, these results are in line with those obtained for viable
tumor cells at RT (Figure 1C).
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Figure W1. Predominantly cytoplasmic CXCR4 expression in in vivo
Ac-TZ12011–FITC–incubated MDAMB231CXCR4+ tumor tissue. (A)
Schematic overview of the principle of intravenously Ac-TZ14011–
FITC incubation: 1. Mice were killed, and the tumor was isolated
24 hours after 50 μg of Ac-TZ14011–FITC was intravenously injected;
2. Tumors were cut into thin slices and placed on a coverslip; 3. Con-
focal imageswere taken. (B)Confocal imagesof live tumor tissue.Orig-
inalmagnification,×630. Controlswere less positive (data not shown).
(C) Freshly isolated tumor tissue was formalin-fixed and imaged. Orig-
inal magnification, ×400. Controls were negative (data not shown).
Table W1. SDF-1 Prevents Binding of 12G5-PE and Ac-TZ14011–FITC to the CXCR4
Receptor (n = 3).
Cell Type
MDAMB231CXCR4+
MFIR ± SD %
12G5-PE 1.485 ± 0.018
SDF-1 + 12G5-PE 1.274 ± 0.033 −14*
Ac-TZ14011–FITC 5.184 ± 0.144
SDF-1 + Ac-TZ14011–FITC 3.699 ± 0.034 −29*
For significance: 12G5-PE/Ac-TZ14011–FITC MFIRs were compared to MFIRs of SDF-1 +
12G5-PE/Ac-TZ14011–FITC incubated conditions.
% indicates percentage change in fluorescent signal intensity.
*P ≤ .005.
